YTTERBIUM YB 169 DTPA
LOE Approachingpentetate calcium trisodium yb-169
NDAINJECTIONINJECTABLEPriority Review
Approved
Mar 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ytterbium Yb-169 DTPA is a radioactive diagnostic agent used in nuclear medicine imaging procedures. It functions as a chelate complex that localizes to specific tissues, enabling visualization and assessment of organ function and pathology. This is a legacy injectable radiopharmaceutical approved nearly 50 years ago.
LOE Approaching
Minimal commercial growth expected; small team focused on maintaining market presence in legacy radiopharmaceutical segment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Ytterbium Yb-169 DTPA presents a career opportunity primarily in legacy product management and compliance roles rather than growth-oriented positions. This product is ideal for professionals seeking stable, specialized expertise in radiopharmaceuticals or transitional roles managing product lifecycle decline.
Product ManagerMarketing Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.